Literature DB >> 20473281

BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression levels in papillary thyroid cancer.

Monica Zerilli1, Giovanni Zito, Anna Martorana, Maria Pitrone, Daniela Cabibi, Francesco Cappello, Carla Giordano, Vito Rodolico.   

Abstract

Hypoxia-inducible factor-1alpha is found frequently overexpressed in solid tumors cells, exerting an important role in angiogenesis, glucose metabolism, cell proliferation, survival and invasion. In thyroid carcinomas, hypoxia-inducible factor-1alpha expression was found increased in differentiated, poorly differentiated, medullary and anaplastic variants. Hypoxia represents the principal stimulus responsible for hypoxia-inducible factor-1alpha induction. Other nonhypoxic stimuli increase hypoxia-inducible factor-1alpha synthesis through the activation of phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways in a cell-type-specific manner. We have previously shown the role of BRAF(V600E) mutation in papillary thyroid cancer cells as a factor that facilitates tumor cell growth and progression. In this study, we tested the hypothesis that BRAF(V600E) mutation influences hypoxia-inducible factor-1alpha expression in papillary thyroid carcinoma cells. We analyzed 27 papillary thyroid carcinomas, 13 of which presented BRAF(V600E) mutation. In tumor tissues, immunoreactivity for hypoxia-inducible factor-1alpha was detected in the majority of analyzed BRAF(V600E) mutated cases. Transcriptional analyses revealed elevated hypoxia-inducible factor-1alpha levels with significant differences between wild-type and mutated group. A BRAF wild-type papillary thyroid carcinoma cell line and a BRAF(V600E) mutated papillary thyroid carcinoma cell line were selected to study the effects of BRAF mutation on hypoxia-inducible factor-1alpha expression in vitro. Knockdown of mutant BRAF(V600E) or both the wild type and the BRAF(V600E) by RNA interference induced a significant reduction of hypoxia-inducible factor-1alpha expression at mRNA and protein levels. Pharmacological inhibition of BRAF significantly reduces hypoxia-inducible factor-1alpha expression levels in papillary thyroid carcinoma cell line harboring BRAF(V600E) mutation. Our results suggest that hypoxia-inducible factor-1alpha is expressed in papillary thyroid carcinomas and is regulated not only by hypoxia but also by BRAF(V600E)-mediated signaling pathway.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20473281     DOI: 10.1038/modpathol.2010.86

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  19 in total

1.  Co-expression of monocarboxylate transporter 1 (MCT1) and its chaperone (CD147) is associated with low survival in patients with gastrointestinal stromal tumors (GISTs).

Authors:  Antônio Talvane Torres de Oliveira; Céline Pinheiro; Adhemar Longatto-Filho; Maria Jose Brito; Olga Martinho; Delcio Matos; André Lopes Carvalho; Vinícius Lima Vazquez; Thiago Buosi Silva; Cristovam Scapulatempo; Sarhan Sydney Saad; Rui Manuel Reis; Fátima Baltazar
Journal:  J Bioenerg Biomembr       Date:  2012-01-27       Impact factor: 2.945

2.  The metabolic microenvironment of melanomas: Prognostic value of MCT1 and MCT4.

Authors:  Céline Pinheiro; Vera Miranda-Gonçalves; Adhemar Longatto-Filho; Anna L S A Vicente; Gustavo N Berardinelli; Cristovam Scapulatempo-Neto; Ricardo F A Costa; Cristiano R Viana; Rui M Reis; Fátima Baltazar; Vinicius L Vazquez
Journal:  Cell Cycle       Date:  2016-04-22       Impact factor: 4.534

3.  Targeting oncogenic serine/threonine-protein kinase BRAF in cancer cells inhibits angiogenesis and abrogates hypoxia.

Authors:  Alessia Bottos; Miriam Martini; Federica Di Nicolantonio; Valentina Comunanza; Federica Maione; Alberto Minassi; Giovanni Appendino; Federico Bussolino; Alberto Bardelli
Journal:  Proc Natl Acad Sci U S A       Date:  2011-12-27       Impact factor: 11.205

4.  Relation between (99m)Tc-tetrofosmin thyroid scintigraphy and mitogen-activated protein kinase in papillary thyroid cancer patients.

Authors:  Kenkichi Baba; Masatoshi Ishibashi; Hayato Kaida; Teruhiko Fujii; Yuji Hiromatsu; Akihiko Kawahara; Masayoshi Kage; Naofumi Hayabuchi
Journal:  Jpn J Radiol       Date:  2011-09-17       Impact factor: 2.374

Review 5.  The association between BRAF (V600E) mutation and pathological features in PTC.

Authors:  Xin Liu; Kangkang Yan; Xuejun Lin; Longyu Zhao; Wenxiu An; Chunpeng Wang; Xiaodong Liu
Journal:  Eur Arch Otorhinolaryngol       Date:  2014-01-04       Impact factor: 2.503

Review 6.  Molecular pathogenesis and mechanisms of thyroid cancer.

Authors:  Mingzhao Xing
Journal:  Nat Rev Cancer       Date:  2013-03       Impact factor: 60.716

Review 7.  Current Standards in Treatment of Radioiodine Refractory Thyroid Cancer.

Authors:  Sujata Narayanan; A Dimitrios Colevas
Journal:  Curr Treat Options Oncol       Date:  2016-06

8.  Expression of hypoxia-inducible factor 1 alpha in papillary thyroid carcinoma is associated with desmoplastic stromal reaction and lymph node metastasis.

Authors:  Oskar Koperek; Erol Akin; Reza Asari; Bruno Niederle; Nikolaus Neuhold
Journal:  Virchows Arch       Date:  2013-10-03       Impact factor: 4.064

Review 9.  Oncogenes and angiogenesis: a way to personalize anti-angiogenic therapy?

Authors:  Alessia Bottos; Alberto Bardelli
Journal:  Cell Mol Life Sci       Date:  2013-05-18       Impact factor: 9.261

10.  In papillary thyroid carcinoma, TIMP-1 expression correlates with BRAF (V600E) mutation status and together with hypoxia-related proteins predicts aggressive behavior.

Authors:  Marius I Ilie; Sandra Lassalle; Elodie Long-Mira; Véronique Hofman; Joséphine Zangari; Gilles Bénaim; Alexandre Bozec; Nicolas Guevara; Juliette Haudebourg; Isabelle Birtwisle-Peyrottes; José Santini; Patrick Brest; Paul Hofman
Journal:  Virchows Arch       Date:  2013-07-27       Impact factor: 4.064

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.